Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fu ...

Core Insights - authID has been selected by a U.S. point-of-sale lending and payment financing platform to enhance its identity verification processes, addressing the rising threat of identity fraud in consumer retail financing [1][2] Industry Context - The selection of authID highlights the increasing demand for biometric identity assurance in the consumer finance sector as fintech platforms face challenges from organized fraud and account takeover attacks that traditional verification methods cannot effectively mitigate [2][4] - In 2024, total U.S. payments fraud losses reached $12.5 billion, with Buy Now Pay Later (BNPL) transactions accounting for 15% of all purchases, indicating a significant risk in this area [5] Company Solutions - To combat fraud, the lender will implement authID Proof™ for identity verification using government-issued IDs during onboarding and authID Verified™ for biometric authentication during account access and high-risk transactions [6] - The platform aims to detect and prevent duplicate and fraudulent applications at onboarding, secure accounts against takeover, and maintain a seamless experience for legitimate users [10] Competitive Advantage - authID's biometric identity verification offers a competitive edge in the commoditized point-of-sale lending market by replacing traditional risk scores and vulnerable authentication methods with deterministic biometric proof, enhancing fraud defenses and customer satisfaction [9] - The company's patented PrivacyKey™ architecture ensures compliance with privacy laws while providing an audit trail based on verified biometrics, further solidifying its market position [8][12] Market Potential - The deployment of authID's solutions is expected to address the high-growth, multi-billion dollar fintech market by verifying the identity of users with industry-leading biometric accuracy in under a second [8][11]

Core Insights - First Watch Restaurant Group, Inc. is participating in three investor conferences in March 2026, including a fireside chat that will be webcast live [1][3] Company Overview - First Watch is a leading Daytime Dining concept specializing in made-to-order breakfast, brunch, and lunch using fresh ingredients [2] - The company follows a "Follow the Sun" culinary philosophy, rotating its chef-driven menu multiple times a year to highlight seasonal flavors [2] - First Watch has raised approximately $2.0 million through donations from kids' meals to support community organizations [2] - The company has received numerous awards, including being voted 1 Best Breakfast by Newsweek's Readers' Choice Awards 2025 and recognized as the 1 Most Loved Workplace in America for 2024 and 2025 [2] - First Watch operates over 630 restaurants across 32 states, focusing on quality, hospitality, and community [2] Upcoming Events - The company will meet with institutional investors at the 47th Annual Raymond James Institutional Investors Conference on March 3, 2026, in Orlando, Florida [3] - First Watch will also participate in the Citi 2026 Global Consumer & Retail Conference on March 9, 2026, in Aventura, Florida [3] - Additionally, the company will attend the Bank of America Consumer & Retail Conference on March 10, 2026, in Miami, Florida [3]

FORT WAYNE, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced that it plans to report results for the fourth quarter and fiscal year ending January 31, 2026 at 8:00 a.m. Eastern Time on Thursday, March 12, 2026. The Company will host a conference call to discuss its financial results at 8:30 a.m. Eastern Time that same day. A live webcast of the conference call will be available on the Company’s website; Investor Relations | Vera Bradley Designs Inc. A ...

Core Insights - Bionano Genomics showcased the advancements of Optical Genome Mapping (OGM) in addressing constitutional genetic disorders at the Bionano Symposium 2026, emphasizing its unique capabilities in detecting structural variants that traditional methods often miss [1][11] Group 1: OGM Applications and Impact - OGM provides unbiased, comprehensive genome-wide structural variant detection, enhancing the interpretation of complex rearrangements in genetic disorders [2] - The technology is transforming research in rare and unresolved disorders by bridging gaps between cytogenetics and molecular genomics, revealing variants overlooked by conventional methods [3] - In a study on autism spectrum disorder (ASD), OGM identified relevant variants in 24% of cases, demonstrating its effectiveness in detecting complex genetic alterations [4] Group 2: Research Findings and Case Studies - OGM has shown utility in reproductive genetics, uncovering cryptic translocations in recurrent pregnancy loss that traditional karyotyping often misses, thus aiding genetic counseling [5] - Studies highlighted OGM's ability to resolve rare constitutional rearrangements and complex copy number variations, improving understanding in unresolved cases across diverse populations [6] - Research demonstrated OGM's capability to detect structural variants associated with conditions like fascioscapulohumeral muscular dystrophy and infertility, emphasizing the need for population-specific OGM databases [7] Group 3: Statistical Insights - In a cohort of 133 subjects with rare diseases, OGM identified pathogenic or likely pathogenic variants in 20% of subjects, with a notable 12% success rate in subjects previously testing negative by chromosomal microarray analysis and whole exome sequencing [9] Group 4: Symposium Highlights and Future Directions - The symposium featured over 1,200 participants from 73 countries, showcasing the global interest in OGM and its applications in genetic research [1] - Panel discussions focused on best practices for OGM implementation and strategies for resolving complex constitutional disorders, indicating a collaborative approach to advancing genetic research [10] - The ongoing symposium will continue to explore genome landscape analysis and feature a scientific poster competition, highlighting the commitment to innovation in genomic research [12]

VERO BEACH, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- BevPoint Capital LP (“BevPoint”), in connection with its proposed transaction with Okmin Resources, Inc. (OTCQB: OKMN) as previously disclosed in filings with the Securities and Exchange Commission (the “SEC”), today announced an ambitious strategic initiative aimed at creating immersive, heritage-based hospitality destinations in multiple markets throughout the US, that celebrate the unique character, culture, and craftsmanship of local communities. BevPo ...

– Training will consist of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart failure patients –TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On Training ...

Core Insights - StoneX Group Inc. has launched a digital asset lending capability through its division, StoneX Digital, enhancing its brokerage and financing services for institutional clients [1][2]. Group 1: Digital Asset Lending Capability - The new lending capability connects institutional clients to digital asset markets, providing spot execution, listed products, and financing solutions within a single framework [2][3]. - This initiative aims to support clients in accessing additional liquidity and capital efficiency while maintaining exposure to digital assets [2][4]. - The initial collateral for the lending program will be Bitcoin, with plans to include additional large-cap digital assets as client demand grows [4]. Group 2: Market Demand and Infrastructure - Institutional market participants are increasingly seeking financing tools that integrate both digital and traditional asset workflows [3]. - StoneX developed this capability to meet the growing demand for integrated digital asset services aligned with established financial market standards [5]. - The lending capability builds on StoneX's existing brokerage and risk management infrastructure, facilitating the integration of digital asset financing into broader portfolio strategies [4]. Group 3: Company Overview - StoneX Digital was launched in June 2022 to provide institutional clients with digital asset trading tools and market access within a regulated framework [5]. - StoneX Group Inc. is a Fortune 50 company headquartered in New York City, serving over 80,000 commercial and institutional clients across more than 80 offices globally [6].

Not for distribution to United States newswire services or for dissemination in the United StatesVANCOUVER, BC, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSXV:FOBI) (Pink: FOBIF) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, advises that its previously announced non-brokered private placement financing (“Offering”) has been granted an extension to close on or before March 12, 2026, or such other date or dates as may be determined ...